

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/51140634>

# Nutrition for Brain Recovery After Ischemic Stroke: An Added Value to Rehabilitation

Article in *Nutrition in Clinical Practice* · June 2011

DOI: 10.1177/0884533611405793 · Source: PubMed

CITATIONS

35

READS

2,036

5 authors, including:



**Roberto Aquilani**

123 PUBLICATIONS 1,858 CITATIONS

[SEE PROFILE](#)



**Paolo Iadarola**

University of Pavia

188 PUBLICATIONS 3,135 CITATIONS

[SEE PROFILE](#)



**Annalisa Barbieri**

University of Pavia

51 PUBLICATIONS 498 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



NMR-based metabolomics of human biofluids, natural extracts and food [View project](#)



OAB treatment [View project](#)

# Nutrition in Clinical Practice

<http://ncp.sagepub.com/>

---

## **Nutrition for Brain Recovery After Ischemic Stroke : An Added Value to Rehabilitation**

Roberto Aquilani, Paolo Sessarego, Paolo Iadarola, Annalisa Barbieri and Federica Boschi

*Nutr Clin Pract* 2011 26: 339

DOI: 10.1177/0884533611405793

The online version of this article can be found at:

<http://ncp.sagepub.com/content/26/3/339>

---

Published by:



<http://www.sagepublications.com>

On behalf of:



[The American Society for Parenteral & Enteral Nutrition](#)

**Additional services and information for *Nutrition in Clinical Practice* can be found at:**

**Email Alerts:** <http://ncp.sagepub.com/cgi/alerts>

**Subscriptions:** <http://ncp.sagepub.com/subscriptions>

**Reprints:** <http://www.sagepub.com/journalsReprints.nav>

**Permissions:** <http://www.sagepub.com/journalsPermissions.nav>

>> [Version of Record](#) - May 16, 2011

[What is This?](#)

# Nutrition for Brain Recovery After Ischemic Stroke: An Added Value to Rehabilitation

Roberto Aquilani, MD<sup>1</sup>; Paolo Sessarego, MD<sup>2</sup>;  
Paolo Iadarola, PhD<sup>3</sup>; Annalisa Barbieri, PhD<sup>4</sup>; and  
Federica Boschi, PhD<sup>4</sup>

*Financial disclosure: none declared.*

In patients who undergo rehabilitation after ischemic stroke, nutrition strategies are adopted to provide tube-fed individuals with adequate nutrition and/or to avoid the body wasting responsible for poor functional outcome and prolonged stay in the hospital. Investigations have documented that nutrition interventions can enhance the recovery of neurocognitive function in individuals with ischemic stroke. Experimental studies have shown that protein synthesis is suppressed in the ischemic penumbra. In clinical studies on rehabilitation patients designed to study the effects of counteracting or limiting this reduction of protein synthesis by providing protein supplementation, patients receiving such supplementation had enhanced recovery of neurocognitive function. Cellular damage in cerebral ischemia is also partly caused by oxidative damage secondary to free radical formation and lipid peroxidation. Increased oxidative stress negatively affects a patient's life and functional prognosis. Some studies

have documented that nutrition supplementation with B-group vitamins may mitigate oxidative damage after acute ischemic stroke. Experimental investigations have also shown that cerebral ischemia changes synaptic zinc release and that acute ischemia increases zinc release, aggravating neuronal injury. In clinical practice, patients with ischemic stroke were found to have a lower than recommended dietary intake of zinc. Patients in whom daily zinc intake was normalized had better recovery of neurological deficits than subjects given a placebo. The aim of this review is to highlight those brain metabolic alterations susceptible to nutrition correction in clinical practice. The mechanisms underlying the relationship between cerebral ischemia and nutrition metabolic conditions are discussed. (*Nutr Clin Pract.* 2011;26:339-345)

**Keywords:** stroke; rehabilitation; dietary supplements, proteins, zinc, oxidative stress

Stroke is currently the third leading cause of death in Western societies. In Italy, the general prevalence of stroke is 6.5%<sup>1</sup>; in 65% of cases the stroke is of an ischemic nature, whereas the other 35% have a hemorrhagic cause. The incidence of ischemic stroke in different age ranges varies from 0.85% (population 65-74 years of age) to 2.2% (population 75-84 years of age) and 3.2% (population ≥85 years of age).<sup>2</sup> The poststroke mortality rate is 20% during the acute period (within 30 days)

and 30% at 1 year. Furthermore, stroke is one of most important causes of disability.<sup>3,4</sup> In Italy, about one-third of patients surviving 1 year after a stroke are totally dependent on other people,<sup>5</sup> creating an enormous socioeconomic burden.

These data should compel physicians dealing with rehabilitation of stroke sequelae to make every effort to obtain the best possible neurological and cognitive recovery of patients. To this aim, interventions planned to enhance the speed of recovery and functional outcome of stroke patients can have great medical importance.

In this context, it is our firm belief that nutrition interventions can enhance the efficacy of stroke rehabilitation. This belief is based on results from animal and human studies showing the existence of metabolic alterations in the brain following acute ischemia and reperfusion and the efficacy of specific nutrition interventions in reducing/reversing brain dysfunction.

In rehabilitation patients with ischemic stroke, nutrition strategies are adopted to provide tube-fed individuals adequate nutrition intakes and/or to avoid the body wasting

From <sup>1</sup>Servizio di Fisiopatologia Metabolico-Nutrizionale e Nutrizione Clinica, Fondazione S. Maugeri, IRCCS, Istituto Scientifico di Montescano, Montescano, Pavia, Italy; <sup>2</sup>Divisione di Neuroriabilitazione, Istituto Scientifico di Genova Nervi, Genova, Italy; <sup>3</sup>Dipartimento di Biochimica A. Castellani, Università degli Studi di Pavia, Pavia, Italy; and <sup>4</sup>Dipartimento di Scienze del Farmaco, Università degli Studi di Pavia, Pavia, Italy.

Address correspondence to: Federica Boschi, Dipartimento di Scienze del Farmaco Università degli Studi di Pavia-Viale Taramelli, 12-27100 Pavia, Italy; e-mail: federica.boschi@unipv.it.

responsible for poor functional outcome and excessively prolonged stay in hospital.<sup>6-8</sup> From 2000 to 2009, a focus on connections between nutrition and the brain developed with interventions planned to target some brain metabolic alterations primed by acute brain ischemia, such as impaired protein synthesis, excess free radical production, and deficiencies of minerals, including zinc.<sup>7,8</sup>

Investigations have documented that recovery of neurocognitive function in individuals with ischemic stroke may indeed be enhanced by nutrition interventions. This is particularly important in light of the following considerations.

- First, no drug acting on damaged brain structures is available in clinical practice for the rehabilitation of patients with ischemic stroke.
- Second, 80% of the recovery of neurological impairment occurs within the first 30 days after acute ischemia,<sup>9,10</sup> which suggests that every effort should be made to obtain the best functional outcomes during this period of rehabilitation.
- Third, a large proportion of patients with stroke may have a catabolic state.<sup>11</sup>
- Fourth, 30 to 35 days after a stroke, patients tend to have the same nutrition deficits as at the time of their admission to a rehabilitation center.<sup>11</sup>
- Fifth, important calorie-protein deficits have been found 6 months after an acute stroke.<sup>12,13</sup>
- Sixth, patients with ischemic stroke have reduced plasma levels of tyrosine, the amino acid precursor of brain adrenergic neurotransmitters (epinephrine, norepinephrine, dopamine).<sup>13</sup>

A better understanding of brain metabolic alterations following cerebrovascular occlusion and the ways to limit them by nutrition would provide the information necessary to improve the functional outcome of stroke patients.

The aim of this review is, therefore, to highlight only those brain metabolic alterations susceptible to nutrition correction in clinical practice.

### Suppression of Brain Protein Synthesis and Nutrition Interventions

Experimental studies have documented that acute ischemia induces early and profound alterations of brain protein synthesis. Indeed, protein synthesis is completely suppressed in the ischemic penumbra<sup>14</sup> (ie, in the region of tissue initially adjacent to the infarct that ultimately progresses to infarction). This suppression is not caused by energy failure or intracellular ion abnormalities, but by alterations of cellular homeostasis, including a reduction in the ratio of guanosine triphosphate to guanosine diphosphate<sup>15</sup> and a lowering of cellular pH before adenosine triphosphate (ATP) decreases.<sup>16</sup>

A decline in amino acid incorporation occurs at blood flow rates as high as 100 mL per 100 g per minute, which suggests that protein synthesis is dissociated from energy metabolism in regions of the brain with focally reduced blood flow. Reduction of protein synthesis begins at blood flow rates approximately 80% of normal,<sup>14</sup> and complete suppression occurs at a net blood flow <40 mL per 100 g per minute. The threshold for protein synthesis is, therefore, much higher than the threshold at which neuronal reduction of ATP formation occurs (<10 mL per 100 g per minute).<sup>17</sup> The consequence is that protein synthesis is inhibited at substantially higher flow values than energy metabolism, suggesting that selective neuronal injury will ensue even at high blood flow levels. There is also strong evidence that dysfunction of the endoplasmic reticulum is involved in the suppression of protein synthesis induced by cerebral ischemia.<sup>18</sup>

The suppression of protein synthesis is clinically relevant. First, if not reversed, inhibition of protein synthesis leads to cell death, and the restoration of protein synthesis may allow cells to repair ischemic damage and recover function.<sup>18</sup> Second, suppression of protein synthesis is paralleled by progression of the infarction zone. It has been found that suppression of protein synthesis leads to neuronal destruction in the ischemic penumbra.<sup>11</sup> Even an isolated blockade of protein synthesis is lethal to cells.<sup>19</sup> Furthermore, suppression of protein synthesis correlates with the final size of the area of ischemic injury much more closely than do energy state or other parameters, including DNA fragmentation.<sup>9</sup> Thus, the inhibition of protein synthesis represents the most reliable parameter heralding the expression of brain infarction.<sup>9</sup>

In humans, the importance of brain protein synthesis for neuronal survival was documented for the first time by an investigation showing the upregulation of growth arrest and DNA damage in the ischemic brain with consequent implications for the regulation of protein synthesis and DNA repair.<sup>20</sup> Alterations of brain protein synthesis can negatively affect brain function in otherwise normal individuals. This was highlighted in an epidemiological study showing neurological disorders in humans with low protein intake.<sup>21</sup>

Several studies on rehabilitation patients, designed to study the effects of counteracting or limiting a reduction of protein synthesis by providing protein supplementation, have shown that patients receiving such supplementation have better recovery of neurocognitive functions. For example, patients given an oral protein supplementation of 20 g/d for 21 days had better recovery of their neurological deficit compared with patients who received a placebo,<sup>17</sup> as determined by scores on the National Institutes of Health Stroke Scale (NIHSS), which quantifies 15 neurological deficits following acute stroke on a scale from 0 (normal neurological condition) to 36 (the most important neurological alterations). The average




Figure 1. Plausible mechanisms for enhanced neurocognitive recovery as a result of protein supplementation in patients with subacute stroke (>14 days from acute event).

reduction of NIHSS score was 4.4 points in patients who received the protein supplementation and 3 points in the controls who did not ( $P < .01$ ). Moreover, protein intake was significantly and positively correlated with improvement in NIHSS score; this was in contrast with the ratio of daily carbohydrate intake (g per day) to protein intake (grams per day). This ratio was positively linked to neurological deficit: at day 21 after starting the protocol, the dietary carbohydrate–protein ratio decreased significantly in the protein-supplemented patients from a baseline value of 3.2 to 2.3, whereas in patients on placebo, the ratio decreased from the baseline value of 3.2 to 2.9. We had previously found that the dietary carbohydrate–protein ratio in healthy subjects aged 40–75 years is  $3.17 \pm 0.8$ , independent of gender (unpublished data).

In another investigation of subacute stroke patients, 21 days of daily supplementation with a formula providing 20 g of protein and 250 kcal (carbohydrate 28.2 g, lipids 7 g in addition to the 20 g of protein) improved cognitive recovery (+3.9 points on the Mini Mental State Examination, MMSE), whereas the baseline MMSE score remained virtually unchanged in the control patients.<sup>22</sup> MMSE is a clinical test that evaluates the patient's cognitive state on a scale from 0 (the most compromised cognitive functions) to 30 (normal cognition).

In further support of these data, we recently documented a positive correlation between spontaneous improvement of neurocognitive deficits and dietary protein intake and a negative correlation with the dietary carbohydrate:protein ratio in patients with subacute stroke.<sup>23</sup>

When considering explanations for the positive influence of protein on brain function, the first point to keep in mind is that the types of cerebral proteins,<sup>24</sup> and hence the amino acid profile in the brain,<sup>25</sup> are influenced by




Figure 2. Improvement in neuronal energy formation by supplemental proteins explaining enhanced neurological recovery in subacute stroke.

the types of dietary proteins. We proposed<sup>11,13,22,23</sup> that multiple mechanisms may account for the efficacy of protein supplementation on brain function of patients with subacute stroke. These mechanisms, primed by increased cerebral availability of amino acids,<sup>26</sup> include a synergistic action between induced brain protein synthesis and rehabilitation procedures (Figure 1),<sup>24,26,27</sup> an improvement in neuron energy formation (Figure 2),<sup>24,26,28</sup> and better neurotransmitter synthesis (Figure 3).<sup>24,26,27,29</sup>

Our investigations pointed to the need to monitor the carbohydrate intake of stroke patients to prevent carbohydrate intake in excess of protein intake because this imbalance slowed neurocognitive recovery 2 weeks after the acute event. That an excess of carbohydrate ingestion can negatively affect recovery from brain dysfunction should not be surprising, given the alterations of brain glucose metabolism occurring in focal cerebral ischemia. Both hyperglycolysis in penumbra cells<sup>30</sup> and reduced aerobic glucose metabolism in cerebral regions remote from the primary ischemic lesion occur in the ischemic brain.<sup>31</sup> In this condition, an excess of carbohydrate




Figure 3. Increased brain neurotransmitter production by supplemental proteins potentially explains recovery in subacute stroke.

ingestion may increase lactate production, resulting in may damage to brain structures.

The reduction in both the efficiency and efficacy of glucose utilization in brain neurons once again highlights the role of amino acids as an alternative fuel for the aerobic production of energy (ATP) in patients with subacute stroke (Figure 2).<sup>24,26,28</sup>

### Brain Oxidative Damage and Nutrition Interventions

Clinical and experimental data have documented that cellular damage in cerebral ischemia is partly caused by oxidative damage secondary to free radical formation and lipid peroxidation.<sup>32</sup> Sources of free radicals include inflammatory cells, xanthine oxidase, cyclooxygenases, mitochondria, glutamate, and aspartate excitotoxic activity.<sup>33</sup>

Free radical overproduction causes oxidative injury to macromolecules, particularly lipids (lipid peroxidation) and proteins. Lipid peroxidation is self-propagating and irreversibly damages both plasma membranes and mitochondrial membranes.<sup>32</sup> Moreover, lipid peroxidation breakdown products, including malondialdehyde, irreversibly damage enzymes, receptors, and membrane transport systems.<sup>34</sup> The  $\text{Na}^+/\text{K}^+$ -ATPase pump appears to be particularly vulnerable, with consequent increased cell death<sup>35</sup> (Figure 4).

Because products of brain lipid peroxidation are transported in the serum, lipid peroxide levels in the serum reflect those present in the brain. Thus, brain damage from free radical overproduction has been documented in humans by measuring plasma concentrations of lipid peroxidation products. Plasma levels of cholesteryl ester hydroperoxide, a specific marker of lipid peroxidation,




Figure 4. Some types of damage that can be caused by free radical overproduction following cerebral ischemia–reperfusion.

were found to be higher in patients with cortical stroke than in patients with lacunar stroke or in normal controls, in whom this analyte was undetectable.<sup>32</sup>

Brain damage from oxidative stress is also inferred from reduced plasma levels of antioxidants, suggesting their increased consumption. This is the case of vitamins E and C, both potent antioxidants, whose levels were decreased in patients with stroke.<sup>36</sup> Moreover, plasma levels of vitamins A and E in patients with acute ischemic stroke were found to be lower than those in healthy controls.<sup>37</sup> Total antioxidant capacity was reduced in patients with acute stroke, and serum vitamin C concentrations deteriorated significantly during the study period.<sup>38</sup>

In brief, brain oxidative damage in ischemic stroke can be inferred from the increased plasma levels of lipid peroxides and/or reduced concentrations and activities of antioxidants. Increased oxidative stress negatively affects a patient's life and functional prognosis. The reduction of total antioxidant activity of plasma is associated with the volume of ischemic cerebral infarction and with the degree of neurological impairment.<sup>39</sup> Moreover, a reduced plasma antioxidant profile is linked to poor early outcome including death or functional decline.<sup>37</sup>

Some studies have documented that nutrition supplementation with B-group vitamins may mitigate oxidative damage after acute ischemic stroke. For example, in a study in which patients were randomized within 12 hours after a brain infarct to receive ( $n = 24$  patients) or not receive ( $n = 24$  patients) 2 weeks of daily supplementation with B-group vitamins, including folate (5 mg),  $\text{B}_2$  (5 mg),  $\text{B}_6$  (50 mg), and  $\text{B}_{12}$  (0.4 mg), those who received the vitamin supplementation not only had a reduction in plasma levels of malondialdehyde over 90 days, but also had lower levels of plasma C-reactive protein, a marker of tissue inflammation, than the controls.<sup>40</sup> Interestingly, the antioxidant and anti-inflammatory effects of the



group B vitamins were independent of their homocysteine-lowering effect.<sup>40</sup> The patients' antioxidant capacity was measured as plasma total antioxidant capacity, whereas plasma malondialdehyde was determined as a marker of lipid peroxidation.

Another study documented the positive effects of supplementary antioxidants (oral vitamin E and vitamin C) on antioxidant capacity of patients with acute ischemic stroke.<sup>41</sup> In this study, 96 patients with acute ischemic stroke admitted within 12 hours of symptom onset were randomly allocated to oral vitamin E (800 international units) and vitamin C (500 mg) ( $n = 24$ ), to B-group vitamins (5 mg of folic acid, 5 mg of vitamin B<sub>2</sub>, 50 mg of vitamin B<sub>6</sub>, 0.4 mg of vitamin B<sub>12</sub>) ( $n = 24$ ), to both types of supplementation ( $n = 24$ ), or to the control group ( $n = 24$ ). Antioxidant capacity was measured as plasma total antioxidant capacity, and plasma malondialdehyde was also measured.

Total antioxidant capacity improved significantly over 7 and 14 days in the antioxidant-only group, whereas capacity declined in the control group. Changes were less marked in subjects who received B-group vitamins with or without antioxidants. There was a significant reduction in plasma malondialdehyde in the 3 treatment groups, in contrast to the increase observed in the control group. The study demonstrated that antioxidant supplementation with or without B-group vitamins enhanced antioxidant capacity, mitigated oxidative damage, and exerted an anti-inflammatory effect immediately after the index event.

The reduction of ischemia-induced oxidative stress in the brain induces rapid defense immune responses and increases antiapoptotic factors, including nuclear factor- $\kappa$ B activity.<sup>42</sup>

Although experimental and human data on brain damage attributed to free-radical overproduction have been collected in acute cerebral ischemia, antioxidant capacity could be expected to decline in rehabilitation patients with stroke because of the acute event and the high frequency of inadequate diet over the first week after a stroke.<sup>11</sup> In the case of low antioxidant capacity, it is important to investigate neurocognitive recovery during nutrition supplementation with antioxidant agents.

## Low Zinc Intake and Nutrition Intervention

Zinc plays an important role in brain functioning because it acts as a mediator of central neuronal signaling, with large amounts being released by synapses during membrane depolarization. This specific neuronal role should be added to the well-known catalytic and structural properties of zinc.<sup>43</sup>

Brain function is affected by both zinc deficiency and excess amounts of zinc. During rapid brain growth, severe

zinc deficiency leads to changes in emotions, lethargy, and deficits of learning, attention, and memory. Elevated brain levels of zinc are neurotoxic because they enhance and prolong the firing rate of neurons and inhibit the calcium-dependent release of transmitters.<sup>44</sup> Experimental investigations have shown that cerebral ischemia changes synaptic zinc release and that acute ischemia increases zinc release, aggravating neuronal injury.<sup>44</sup> Even mild and transient focal ischemia induces abnormal zinc accumulation in cortical neurons within 3 hours, thus accelerating the development of cerebral infarction.<sup>10</sup>

It has been documented that zinc chelators reduce infarct volume and increase survival rate in rat models of cerebral ischemia.<sup>45</sup> In a clinical study, zinc chelators were associated with a 90-day improvement in post-stroke recovery in patients with acute ischemic stroke.<sup>46</sup>

In contrast to the reports of zinc neurotoxicity in ischemia, various studies found that administration of the mineral provided neuroprotection by reducing ischemic brain edema<sup>47</sup> and attenuating infarct volume after both transient focal and global ischemia.<sup>48</sup> Systemic administration of zinc was also found to have positive effects on the hippocampus during reperfusion in a rat model of transient cerebral ischemia.<sup>49</sup>

These conflicting data about zinc neurotoxicity and neuroinfarction may be explained by differences in methodological designs.

In clinical practice, dietary zinc intake by patients with ischemic stroke was found to be lower than the recommended 10 mg/d. In confirmation of this, in a recent investigation on subacute ischemic stroke, our group found that zinc intake by patients averaged about 50% of the recommended amount.<sup>50</sup> When patients were randomized to receive either 10 mg of zinc supplementation per day for 30 days to normalize daily zinc intake, or placebo, subjects who received supplementation had a better recovery of neurological deficit (as determined by the NIHSS score) than did placebo subjects. Indeed, the average reduction in NIHSS score was 4.7 in the supplemented subjects and 3.3 in the placebo group,<sup>50</sup> with this difference between the 2 groups of patients being statistically significant ( $P < .02$ ). We explained the positive influence of normalized zinc intake on neurological recovery by mechanisms such as brain reactivation of protein synthesis, improved chemical neurotransmission, and repair of cerebral damage (Figure 5).<sup>11,22,50</sup>

## Conclusions

There are 2 practical implications of this report regarding the relationship between nutrition and cerebral function in subjects undergoing rehabilitation after stroke.




Figure 5. Potential effects of normalized zinc intake on improving brain function.

First, inadequate protein intake, low zinc intake, and low antioxidant capacity are all associated with expansion of ischemia-induced brain damage. Second, this brain damage can be reversed by specific nutrition interventions. In certain cases, nutrition interventions can be beneficial to rehabilitation of patients with ischemic stroke. This appears to be even more important when considering that nutrition interventions consist of providing natural substances and that in clinical practice there are no known drugs that modulate brain recovery.

While awaiting larger trials addressing the effects of nutrition and nutrition interventions on the recovery of brain function in ischemic stroke patients, some indications useful in clinical practice and derived from existing investigations can be provided:

1. In both acute and postacute (>7-14 days from event) stroke, it is preferable to determine the patient's plasma antioxidant capacity. If this is not feasible, the antioxidant vitamins E and C can be supplied.
2. In the subacute period, the following daily nutrition intakes might be recommended in clinically stable patients with normal renal function:
  - a. Energy:  $\geq 25$  kcal/kg in nonobese subjects to maintain body weight; in the case of overweight/obese subjects given energy  $< 25$  kcal/kg, it is recommended to maintain a carbohydrate-protein ratio  $< 2.5$ .
  - b. Protein:  $> 1$  g/kg in order to achieve carbohydrate (g)-protein (g) ratio  $< 2.5$ . For example, for a patient weighing 70 kg, an appropriate nutrition intake might be kcal 1,750, protein 1.5 g/kg (=24% energy), carbohydrate 3.12 g/kg (=50% energy), carbohydrate-protein ratio 2.08, lipids 0.72 g/kg (= 26% energy).
  - c. Self-feeding subjects should eat a portion of lean meat or poultry or fish at least once a day to achieve a total zinc intake of 12-15 mg.

## References

1. Spread National Stroke Guidelines. Italian National Health Service, 2001. [www.sanita.it](http://www.sanita.it).
2. Di Carlo A, Baldereschi M, Gandolfo C, et al. ILSA Working Group. *Stroke in an elderly population: incidence and impact on survival and daily function. The Italian Longitudinal Study on Aging. Cerebrovasc Dis.* 2003;16:141-150.
3. Abbott RD, Donahue RP, MacMahon SW, Reed DM, Yano K. Diabetes and the risk of stroke: the Honolulu Heart Program. *JAMA.* 1987;257:949-952.
4. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. *Med J Aust.* 2000;172:592-596.
5. Scholte op Reimer WJ, de Haan RJ, Rijnders PT, Limburg M, van den Bos GA. The burden of caregiving in partners of long-term stroke survivors. *Stroke.* 1998;29:1605-1611.
6. Finestone HM, Greene-Finestone LS, Wilson ES, Teasell RW. Malnutrition in stroke patients on the rehabilitation service and at follow-up: prevalence and predictors. *Arch Phys Med Rehabil.* 1995;76:310-316.
7. Aquilani R, Galli M, Guarnaschelli C, et al. Prevalence of malnutrition and inadequate food intake in self-feeding rehabilitation patients with stroke. *Eur Medicophys.* 1999;35:75-81.
8. Gariballa SE, Parker SG, Taub N, Castleden CM. Influence of nutritional status on clinical outcome after acute stroke. *Am J Clin Nutr.* 1998;68:275-281.
9. Hata R, Maeda K, Hermann D, Mies G, Hossmann KA. Dynamics of regional brain metabolism and gene expression after middle cerebral artery occlusion in mice. *J Cereb Blood Flow Metab.* 2000;20:306-315.
10. Lee JM, Zipfel GJ, Park KH, He YY, Hsu CY, Choi DW. Zinc translocation accelerates infarction after mild transient focal ischemia. *Neuroscience.* 2002;115:871-878.
11. Aquilani R, Scocchi M, Iadarola P, et al. Protein supplementation may enhance the spontaneous recovery of neurological alterations in patients with ischaemic stroke. *Clin Rehabil.* 2008;22:1042-1050.
12. Perry L. Eating and dietary intake in communication-impaired stroke survivors: a cohort study from acute-stage hospital admission to 6 months post-stroke. *Clin Nutr.* 2004;23:1333-1343.
13. Aquilani R, Verri M, Iadarola P, et al. Plasma precursors of brain catecholaminergic and serotonergic neurotransmitters in rehabilitation patients with ischemic stroke. *Arch Phys Med Rehabil.* 2004;85:779-784.



14. Xie Y, Mies G, Hossmann KA. Ischemic threshold of brain protein synthesis after unilateral carotid artery occlusion in gerbils. *Stroke*. 1989;20:620-626.
15. Dwyer B, Wasterlain CG. Regulation of the first step of the initiation of brain protein synthesis by guanosine diphosphate. *J Neurochem*. 1980;34:1639-1647.
16. Hossmann KA, Mies G, Paschen W, et al. Multiparametric imaging of blood flow and metabolism after middle cerebral artery occlusion in cats. *J Cereb Blood Flow Metab*. 1985;5:97-107.
17. Hossmann KA, Schuier FJ. Experimental brain infarcts in cats, I: pathophysiological observations. *Stroke*. 1980;11:583-592.
18. Paschen W. Shutdown of translation: lethal or protective? Unfolded protein response versus apoptosis. *J Cereb Blood Flow Metab*. 2003;23:773-779.
19. Srivastava SP, Kumar KU, Kaufman RJ. Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase. *J Biol Chem*. 1998;273:2416-2423.
20. White F, McCaig D, Brown SM, Graham DI, Harland J, Macrae IM. Up-regulation of a growth arrest and DNA damage protein (GADD34) in the ischaemic human brain: implications for protein synthesis regulation and DNA repair. *Neuropathol Appl Neurobiol*. 2004;30:683-691.
21. Román GC. Epidemic neuropathy in Cuba: a plea to end the United States economic embargo on a humanitarian basis. *Neurology*. 1994;44:1784-1786.
22. Aquilani R, Scocchi M, Boschi F, et al. Effect of calorie-protein supplementation on the cognitive recovery of patients with subacute stroke. *Nutr Neurosci*. 2008;11:235-240.
23. Aquilani R, Scocchi M, Iadarola P, et al. Spontaneous neurocognitive retrieval of patients with sub-acute ischemic stroke is associated with dietary protein intake. *Nutr Neurosci*. 2010;13:129-134.
24. Bourre JM. The role of nutritional factors on the structure and function of the brain: an update on dietary requirements. *Rev Neurol (Paris)*. 2004 Sep;160(8-9):767-92.
25. Choi YH, Chang N, Fletcher PJ, Anderson GH. Dietary protein content affects the profiles of extracellular amino acids in the medial preoptic area of freely moving rats. *Life Sci*. 2000 Feb 11;66(12):1105-18.
26. Faournoux P, Bruhat A, Jousse C. Amino acid regulation of gene expression. *Biochem J*. 2000 Oct 1;351(Pt 1):1-12.
27. Dobkin BH. Strategies for stroke rehabilitation. *Lancet Neurol*. 2004 Sep;3(9):528-36.
28. Paschen W, Frandsen A. Endoplasmic reticulum dysfunction - a common denominator for cell injury in acute and degenerative diseases of the brain? *J Neurochem*. 2001 Nov;79(4):719-25.
29. Sawaki L, Cohen LG, Classen J, Davis BC, Bütefisch CM. Enhancement of use-dependent plasticity by D-amphetamine. *Neurology*. 2002 Oct 22;59(8):1262-4.
30. Back T, Zhao W, Ginsberg MD. Three-dimensional image analysis of brain glucose metabolism-blood flow uncoupling and its electrophysiological correlates in the acute ischemic penumbra following middle cerebral artery occlusion. *J Cereb Blood Flow Metab*. 1995 Jul;15(4):566-77.
31. Pantano P, Baron JC, Samson Y, Boussier MG, Derouesne C, Comar D. Crossed cerebellar diaschisis: further studies. *Brain*. 1986;109(pt 4):677-694.
32. Polidori MC, Frei B, Cherubini A, et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. *Free Radic Biol Med*. 1998;25:561-567.
33. Morimoto T, Globus MY, Busto R, Martinez E, Ginsberg MD. Simultaneous measurement of salicylate hydroxylation and glutamate release in the penumbral cortex following transient middle cerebral artery occlusion in rats. *J Cereb Blood Flow Metab*. 1996;16:92-99.
34. Oh SM, Betz AL. Interaction between free radicals and excitatory amino acids in the formation of ischemic brain edema in rats. *Stroke*. 1991;22:915-921.
35. Siems WG, Hapner SJ, van Kuijk FJ. 4-hydroxynonenal inhibits Na(+)-K(+)-ATPase. *Free Radic Biol Med*. 1996;20:215-223.
36. Sharpe PC, Mulholland C, Trinick T. Ascorbate and malondialdehyde in stroke patients. *Ir J Med Sci*. 1994;163:488-491.
37. Cherubini A, Polidori MC, Bregnocchi M, et al. Antioxidant profile and early outcome in stroke patients. *Stroke*. 2000;31:2295-2300.
38. Gariballa SE, Hutchin TP, Sinclair AJ. Antioxidant capacity after acute ischaemic stroke. *QJM*. 2002;95:685-690.
39. Leinonen JS, Ahonen JP, Lönnrot K, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. *Stroke*. 2000;31:33-39.
40. Ullegaddi R, Powers HJ, Gariballa SE. B-group vitamin supplementation mitigates oxidative damage after acute ischaemic stroke. *Clin Sci (Lond)*. 2004;107:477-484.
41. Ullegaddi R, Powers HJ, Gariballa SE. Antioxidant supplementation with or without B-group vitamins after acute ischemic stroke: a randomized controlled trial. *JPN J Parenter Enteral Nutr*. 2006;30:108-114.
42. Song YS, Lee YS, Narasimhan P, Chan PH. Reduced oxidative stress promotes NF-kappaB-mediated neuroprotective gene expression after transient focal cerebral ischemia: lymphocytotropic cytokines and antiapoptotic factors. *J Cereb Blood Flow Metab*. 2007;27:764-775.
43. O'Halloran TV. Transition metals in control of gene expression. *Science*. 1993;261:715-725.
44. Koh JY, Suh SW, Gwag BJ, He YY, Hsu CY, Choi DW. The role of zinc in selective neuronal death after transient global cerebral ischemia. *Science*. 1996;272:1013-1016.
45. Angel I, Bar A, Horovitz T, et al. Metal ion chelation in neurodegenerative disorders. *Drug Dev Res*. 2002;56:300-309.
46. Diener HC, Schneider D, Lampl Y, Bornstein NM, Kozak A, Rosenberg G. DP-b99, a membrane-activated metal ion chelator, as neuroprotective therapy in ischemic stroke. *Stroke*. 2008;39:1774-1778.
47. Zhao YJ, Yang GY, Domino EF. Zinc protoporphyrin, zinc ion, and protoporphyrin reduce focal cerebral ischemia. *Stroke*. 1996;27:2299-2303.
48. Fujimura M, Morita-Fujimura Y, Noshita N, Sugawara T, Kawase M, Chan PH. The cytosolic antioxidant copper/zinc-superoxide dismutase prevents the early release of mitochondrial cytochrome c in ischemic brain after transient focal cerebral ischemia in mice. *J Neurosci*. 2000;20:2817-2824.
49. Helal GK. Systemic administration of Zn<sup>2+</sup> during the reperfusion phase of transient cerebral ischaemia protects rat hippocampus against iron-catalysed postischaemic injury. *Clin Exp Pharmacol Physiol*. 2008;35:775-781.
50. Aquilani R, Baiardi P, Scocchi M, et al. Normalization of zinc intake enhances neurological retrieval of patients suffering from ischemic strokes. *Nutr Neurosci*. 2009;12:219-225.